BioCentury
ARTICLE | Clinical News

Next up for GlycoMimetics after tanking in sickle cell disease

August 6, 2019 12:18 AM UTC

Despite plunging 69% to $2.80 on Monday after the Phase III miss of sickle cell disease candidate rivipansel, GlycoMimetics could still turn things around. The small cap has another shot on goal with Phase III AML candidate uproleselan and $184.2 million in cash to get it to the compound's next readout by YE20.

After hours Friday, GlycoMimetics Inc. (NASDAQ:GLYC) said that a Phase III trial of its pan-selectin antagonist IV rivipansel failed to meet its primary endpoint of readiness-for-discharge in sickle cell patients hospitalized for a vaso-occlusive crisis (VOC) and requiring IV opioids. The drug also did not meet the trial’s secondary endpoints of time-to-discharge, cumulative IV opioid consumption, and time-to-discontinuation of IV opioids...

BCIQ Company Profiles

GlycoMimetics Inc.